Canary Wharf (BP4) T1 Limited and others v European Medicines
Agency is the first major property dispute with Brexit at its heart
and is currently being determined by the High Court. Depending on
its outcome, the case may result in a flurry of Brexit-related
litigation in the months to come. These are likely to involve much
wider sectors such as banking, finance and trade and not be
confined to the property market. The ramifications for the wider
economy would be significant.
Background and facts
In 2011, the European Medicines Agency (the
EMA) entered into an agreement for lease for a 25
year term in respect of Churchill Place – a newly-constructed
10 floor building in Canary Wharf. The lease was entered into in
2014, however it crucially did not contain a break right allowing
for early termination.
